Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Synlogic (SYBX) is now available.
Synlogic, Inc. has appointed James Flynn as a new Class I Director to its Board of Directors, with his term expiring at the 2026 annual stockholders’ meeting. Flynn brings a wealth of experience as a healthcare investment specialist, with prior roles at Nerium Capital LLC, ARCA Biopharma, and Amici Capital. Concurrently, directors Mike Burgess, Lisa Kelly-Croswell, and Patricia N. Hurter have resigned, citing no disagreements with the company. Flynn’s appointment is complemented by an incentivizing stock option grant and a standard indemnification agreement.
See more insights into SYBX stock on TipRanks’ Stock Analysis page.